Last reviewed · How we verify
Indinavir (IDV)
Indinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.
Indinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles. Used for HIV-1 infection.
At a glance
| Generic name | Indinavir (IDV) |
|---|---|
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Indinavir binds to the active site of HIV protease, a viral enzyme essential for processing precursor proteins into functional structural and enzymatic proteins. By inhibiting this protease, the drug prevents the formation of mature, infectious viral particles, thereby reducing viral replication and slowing disease progression in HIV-infected patients.
Approved indications
- HIV-1 infection
Common side effects
- Nephrolithiasis (kidney stones)
- Gastrointestinal disturbances (nausea, diarrhea)
- Headache
- Hyperbilirubinemia
- Lipodystrophy
- Hyperglycemia
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- A Prospective Cohort of Children With HIV Infection
- Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma (PHASE2)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |